Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors
In summary, we successfully identified and optimized STK17B kinase inhibitors which led to increased T cell responses <i>in vitro</i> and <i>in vivo</i>. This allowed us to evaluate the potential of STK17B inhibition as an approach for cancer immunotherapy.
Authors
- Tary Traore
- Emanuele Perola
- Jan Eckmann (ORCID: https://orcid.org/0009-0008-0829-9576)
- Joseph L. Kim (ORCID: https://orcid.org/0000-0002-7739-2343)
- Richard Woessner
- Katie McGinn
- Marion Dorsch
- Caitlin Kinkema
- Florian Renner (ORCID: https://orcid.org/0000-0003-3326-0303)
- Ulrike Hopfer
- Manuel Tzouros (ORCID: https://orcid.org/0000-0002-6782-5520)
- Chris De Savi
- Felix Scheuplein (ORCID: https://orcid.org/0000-0002-2691-0796)
- Nisha Perez
- Arndt‐Christian Müller (ORCID: https://orcid.org/0000-0002-6539-0682)
- Jie Ge (ORCID: https://orcid.org/0000-0002-4186-4740)
- Peter M. Jakob (ORCID: https://orcid.org/0000-0002-3481-5545)
- Ruduan Wang
- Stefka Tyanova (ORCID: https://orcid.org/0000-0002-1974-5876)
- Luke Green
- Ricardo Medina (ORCID: https://orcid.org/0000-0001-5561-5481)
- John E. Campbell
- Holger Fischer
- Robert C. Campbell
- James R. Bischoff
- Yoav Timsit
Institutions
- Roche (Switzerland) (CH)
- Roche Pharma AG (Germany) (DE)
- Blueprint Medicines (United States) (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-21
- DOI
- https://doi.org/10.3389/fimmu.2024.1411395
- Citations
- 3
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- F. Hoffmann-La Roche